The rate of new lung cancer cases decreased among men and women from 2005 to 2009, largely due to tobacco control efforts, according to a report from the Centers for Disease Control and Prevention.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
